NPT1220-312 / EVER Pharma - LARVOL DELTA

NPT1220-312, a TLR2/TLR9 Small Molecule Antagonist, Inhibits Pro-Inflammatory Signaling, Cytokine Release, and NLRP3 Inflammasome Activation. (PubMed, Int J Inflam) - "The ability of NPT1220-312 to inhibit TLR2 mediated pro-inflammatory release of chemokines and cytokines in situ was demonstrated using murine and human whole blood. Together, these findings suggest that blockade of TLR2 and TLR9 may reduce inappropriate production of pro-inflammatory cytokines and chemokines from peripheral and central immune cells and thus potentially provide therapeutic benefit in neuroinflammatory/neurodegenerative disorders."

IO biomarker • Journal • CNS Disorders • IL18 • IL1B • NLRP3 • TLR9

[VIRTUAL] TLR2 INHIBITION BLOCKS INFLAMMATION AND REDUCES INTRACELLULAR PROTEIN ACCUMULATION TO REDUCE PROTEIN PATHOLOGY IN MULTIPLE PRE-CLINICAL MODELS OF NEURODEGENERATION (AAT-ADPD 2020) - "Neuropore has developed a peripheral TLR2 target engagement biomarker to support clinical development and pre-clinical in vitro safety evaluations have found no liabilities to-date for Neuropore’s small molecule TLR2 antagonists. Conclusions Neuropore continues with the preclinical development of NPT1220-312 in support of an Investigational New Drug (IND) submission in 2020."

ALS association awards Neuropore $500K to advance potential anti-inflammatory therapy (ALS News Today) - “Neuropore Therapies was awarded a $500,000 grant from The ALS Association to advance in preclinical work its neural protective candidate, NPT1220-312, as a potential treatment of amyotrophic lateral sclerosis (ALS)….‘Pending positive outcomes in ongoing studies, our goal is to submit an IND [investigational new drug] application for NPT1220-312 to FDA by first half of 2021.’”

Grant • IND

Neuropore Therapies receives $500,000 grant from The ALS Association to explore ALS treatments that inhibit neuronal damage from disease-related inflammation (Businesswire) - “Neuropore Therapies…announced today that it has been awarded a $500,000 grant from The ALS Association to support the preclinical evaluation and development of its leading Toll-Like Receptor 2 (TLR2) antagonist NPT1220-312 for the treatment of amyotrophic lateral sclerosis.'…our goal is to submit an IND application for NPT1220-312 to FDA by first half of 2021.’”

Grant • IND